Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017
23 août 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study...
Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
14 août 2017 08h15 HE
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
01 août 2017 16h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on the development...
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
13 juin 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
Autoimmune Disease Patent Granted to Galectin Therapeutics
06 juin 2017 08h30 HE
|
Galectin Therapeutics
NORCROSS, Ga., June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
01 juin 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., June 01, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced the dosing of the first patients in Part Two of a...
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2
26 mai 2017 09h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update
09 mai 2017 16h05 HE
|
Ocera Therapeutics, Inc.
Post-hoc per protocol analysis demonstrates OCR-002 achieved primary endpoint with statistical significance, p=0.034 Company to host conference call and webcast today at 4:30 p.m. ET REDWOOD CITY,...
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017
03 mai 2017 16h05 HE
|
Ocera Therapeutics, Inc.
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., May 03, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
18 avr. 2017 08h00 HE
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...